Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.
Public Policy, USC Schaeffer Center for Health Policy & Economics, Los Angeles, CA, USA.
Int J Technol Assess Health Care. 2024 Mar 5;40(1):e17. doi: 10.1017/S0266462324000138.
This research sought to assess whether and how patient preference (PP) data are currently used within health technology assessment (HTA) bodies and affiliated organizations involved in technology/drug appraisals and assessments. An exploratory survey was developed by the PP Project Subcommittee of the HTA International Patient and Citizen Involvement Interest Group to gain insight into the use, impact, and role of PP data in HTA, as well as the perceived barriers to its incorporation. Forty members of HTA bodies and affiliated organizations from twelve countries completed the online survey. PP data were reported to be formally considered as part of the HTA evidence review process by 82.5 percent of the respondents, while 39.4 percent reported that most of the appraisals and assessments within their organization in the past year had submitted PP data. The leading reason for why PP data were not submitted in most assessments was time/resource constraints followed by lack of clarity on PP data impact. Participants reported that PP data had a moderate level of influence on the deliberative process and outcome of the decision, but a higher level of influence on the decision's quality. Most (81.8 percent) felt patient advocacy groups should be primarily responsible for generating and submitting this type of evidence. Insights from the survey confirm the use of PP data in HTA but reveal barriers to its broader and more meaningful integration. Encouragingly, participants believe obstacles can be overcome, paving the way for a second phase of research involving in-depth collaborative workshops with HTA representatives.
这项研究旨在评估在参与技术/药物评估和评估的健康技术评估 (HTA) 机构和附属组织中，目前是否以及如何使用患者偏好 (PP) 数据。HTA 国际患者和公民参与利益小组的 PP 项目小组委员会开发了一项探索性调查，以深入了解 PP 数据在 HTA 中的使用、影响和作用，以及将其纳入的感知障碍。来自十二个国家的 HTA 机构和附属组织的 40 名成员完成了在线调查。82.5%的受访者报告称，PP 数据被正式视为 HTA 证据审查过程的一部分，而 39.4%的受访者报告称，他们所在组织过去一年的大部分评估和评估都提交了 PP 数据。在大多数评估中未提交 PP 数据的主要原因是时间/资源限制，其次是对 PP 数据影响的不明确。参与者报告称，PP 数据对审议过程和决策结果有中等程度的影响，但对决策质量的影响更大。大多数人（81.8%）认为患者倡导团体应该主要负责生成和提交此类证据。调查结果证实了在 HTA 中使用 PP 数据，但也揭示了其更广泛和更有意义的整合的障碍。令人鼓舞的是，参与者认为可以克服障碍，为下一阶段的研究铺平道路，下一阶段的研究将与 HTA 代表进行深入的合作研讨会。
